Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Detection of the calreticulin type 1 and type 2 mutations in a group of myeloproliferative neoplasm patients using molecular methods

Dissertation (MSc)--University of Pretoria, 2016.

Saved in:
Bibliographic Details
Other Authors: Van Zyl, Walda B.
Format: Thesis
Language:English
Published: University of Pretoria 2017
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867613443455975424
access_status_str Open Access
author2 Van Zyl, Walda B.
author_browse Van Zyl, Walda B.
author_facet Van Zyl, Walda B.
collection Thesis
dc_rights_str_mv © 2017 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria.
description Dissertation (MSc)--University of Pretoria, 2016.
format Thesis
id oai:repository.up.ac.za:2263/61682
institution University of Pretoria (South Africa)
language English
last_indexed 2026-06-10T12:36:13.892Z
license_str Other — see source repository
provenance_str_mv Harvested via OAI-PMH from UPSpace — University of Pretoria Institutional Repository
publishDate 2017
publishDateRange 2017
publishDateSort 2017
publisher University of Pretoria
publisherStr University of Pretoria
record_format dspace
source_str UPSpace — University of Pretoria Institutional Repository
spelling oai:repository.up.ac.za:2263/61682 Detection of the calreticulin type 1 and type 2 mutations in a group of myeloproliferative neoplasm patients using molecular methods Van Zyl, Walda B. louisedutoit@yahoo.com Prinsloo, A. (Adri) Du Toit, Louise de Villiers UCTD Calreticulin mutations Myeloproliferative neoplasms Molecular methods Mutation detection Hematological malignancies Genomic analysis Diagnostic biomarkers Genetic testing PCR (Polymerase Chain Reaction) Next-generation seque Health sciences theses SDG-03 SDG-03: Good health and well-being Health sciences theses SDG-09 SDG-09: Industry, innovation and infrastructure Health sciences theses SDG-10 SDG-10: Reduced inequalities Health sciences theses SDG-17 SDG-17: Partnerships for the goals Dissertation (MSc)--University of Pretoria, 2016. The myeloproliferative neoplasms (MPN), formerly referred to as chronic myeloproliferative disorders, are a group of haematopoietic stem cell disorders that are characterized by clonal proliferation of one or more mature myeloid lineages. The group of disorders, now classified as the classic MPNs, include chronic myeloid leukaemia (CML), as well as the Philadelphia (Ph) chromosome-negative MPNs: polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) or myelofibrosis (MF). In 2013, somatic mutations at exon 9 of CALR, the gene that encodes for calreticulin, were discovered through whole-exome sequencing and targeted re-sequencing in patients with MPNs. Among these mutations, more than 80% of CALR mutated patients possessed one of only two mutation types: type 1 (a 52-bp deletion) and type 2 (a 5-bp insertion). In MPNs, patients positive for a mutation in their calreticulin gene have shown milder symptoms and an overall better survival rate than patients who had one of the other common phenotypic driver mutations i.e. JAK2 or MPL. Determining which driver mutation is responsible for the manifestation of the MPN is therefore important in monitoring the treatment and prognosis of the patient. In the South African sector, a simple, efficient, cost effective and sensitive detection method for testing for CALR type 1 and type 2 mutations is necessary to fill the current diagnostic gap regarding the diagnosis of MPNs. This study aimed to evaluate the use of conventional PCR followed by restriction enzyme digestion, confirmation of the PCR results by nucleotide sequencing, as well as real-time PCR (qPCR) to detect these mutations. A conventional PCR commercial kit was also compared to that of the developed conventional PCR. For this study 24 blood samples were collected from the tertiary hospital haematology clinic, 24 archived DNA samples from a colleague's previous JAK2 mutation study were used and two DNA samples were obtained from a private pathology laboratory. A total of 50 samples were thus analysed. The newly developed in-house conventional PCR was successful in detecting the CALR type 1 and type 2 mutations in patients and the results were confirmed by Sanger sequencing. The results obtained using the commercial conventional PCR kit corresponded 100% with the results obtained by the in-house conventional PCR assay, followed by restriction enzyme digestion and finally confirmation of results by nucleotide sequencing analysis. The kit was, however, much more expensive than the in-house PCR assay. The qPCR using SYBR Green as well as the qPCR using probes were unable to detect the type 1 and type 2 mutations and further troubleshooting was not possible due to budgetary constraints. Overall, 3/50 patients contained the type 1 mutation and 2/50 contained the type 2 mutation, indicating the possibility of a low prevalence for the CALR type 1 and type 2 mutations in the South African population. em2025 Haematology MSc Unrestricted SDG-03: Good health and well-being SDG-09: Industry, innovation and infrastructure SDG-10: Reduced inequalities SDG-17: Partnerships for the goals 2017-08-15T12:35:35Z 2017-08-15T12:35:35Z 2017-05-05 2016 Dissertation Du Toit, LDV 2016, Detection of the calreticulin type 1 and type 2 mutations in a group of myeloproliferative neoplasm patients using molecular methods, MSc Dissertation, University of Pretoria, Pretoria, viewed yymmdd <http://hdl.handle.net/2263/61682> A2017 http://hdl.handle.net/2263/61682 en © 2017 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria. application/pdf University of Pretoria
spellingShingle UCTD
Calreticulin mutations
Myeloproliferative neoplasms
Molecular methods
Mutation detection
Hematological malignancies
Genomic analysis
Diagnostic biomarkers
Genetic testing
PCR (Polymerase Chain Reaction)
Next-generation seque
Health sciences theses SDG-03
SDG-03: Good health and well-being
Health sciences theses SDG-09
SDG-09: Industry, innovation and infrastructure
Health sciences theses SDG-10
SDG-10: Reduced inequalities
Health sciences theses SDG-17
SDG-17: Partnerships for the goals
Detection of the calreticulin type 1 and type 2 mutations in a group of myeloproliferative neoplasm patients using molecular methods
title Detection of the calreticulin type 1 and type 2 mutations in a group of myeloproliferative neoplasm patients using molecular methods
title_full Detection of the calreticulin type 1 and type 2 mutations in a group of myeloproliferative neoplasm patients using molecular methods
title_fullStr Detection of the calreticulin type 1 and type 2 mutations in a group of myeloproliferative neoplasm patients using molecular methods
title_full_unstemmed Detection of the calreticulin type 1 and type 2 mutations in a group of myeloproliferative neoplasm patients using molecular methods
title_short Detection of the calreticulin type 1 and type 2 mutations in a group of myeloproliferative neoplasm patients using molecular methods
title_sort detection of the calreticulin type 1 and type 2 mutations in a group of myeloproliferative neoplasm patients using molecular methods
topic UCTD
Calreticulin mutations
Myeloproliferative neoplasms
Molecular methods
Mutation detection
Hematological malignancies
Genomic analysis
Diagnostic biomarkers
Genetic testing
PCR (Polymerase Chain Reaction)
Next-generation seque
Health sciences theses SDG-03
SDG-03: Good health and well-being
Health sciences theses SDG-09
SDG-09: Industry, innovation and infrastructure
Health sciences theses SDG-10
SDG-10: Reduced inequalities
Health sciences theses SDG-17
SDG-17: Partnerships for the goals
url http://hdl.handle.net/2263/61682